Biosimilar Battlefield: The Remsima/Inflectra Warning
2019 marks an inflection point for Korean biosimilar companies Celltrion Healthcare (091990 KS), Celltrion Inc (068270 KS), and Samsung Biologics...
694 Views
Amarin--2019's Biggest Buyout Target for Big Pharma
Amarin (AMRN US), a US-listed biotech firm, presented the full results of its "Reduce-It" (RI) clinical trial at a conference for the American...
4.7k Views
J&J Tenders for Ci:z Holdings
Today after the close, Johnson & Johnson (JNJ US)announced a US$2bn+ deal and Tender Offer to buy the 52% of Ci:z Holdings (4924 JP) not held...
582 Views
Celltrion Inc Placement - Shorter Lockup Period Will Be an Overhang for Share Price
Ion Investment (Temasek) is looking to sell about 3.4m shares in Celltrion Inc (068270 KS) in an accelerated bookbuild worth approximately US$740m....
502 Views
Celltrion: Understanding Inflectra's U.S. Challenges
Celltrion Inc (068270 KS) 's Inflectra (biosimilar of Remicade marketed in the U.S.) has struggled to gain a foothold in the market since its...
614 Views